These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30689744)

  • 1. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
    Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG
    Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
    Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
    Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
    Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
    Boyce EG; Mai Y; Pham C
    Ann Pharmacother; 2018 May; 52(5):462-472. PubMed ID: 29241341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
    Sheth NP; Smith JR; Winzenrieth R; Humbert L; Wang Y; Boxberger JI; Bostrom MP
    J Bone Joint Surg Am; 2024 Jul; 106(13):1162-1170. PubMed ID: 38691582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.
    Reginster JY; Al Daghri NM; Bruyere O
    Expert Opin Pharmacother; 2017 Dec; 18(17):1811-1813. PubMed ID: 29048260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
    Czerwinski E; Cardona J; Plebanski R; Recknor C; Vokes T; Saag KG; Binkley N; Lewiecki EM; Adachi J; Knychas D; Kendler D; Orwoll E; Chen Y; Pearman L; Li YH; Mitlak B
    J Bone Miner Res; 2022 Dec; 37(12):2435-2442. PubMed ID: 36190391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
    Merlotti D; Falchetti A; Chiodini I; Gennari L
    Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
    Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
    Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
    Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.